On October 18, 2016, atezolizumab (Tecentriq; Genentech), a PD-L1 inhibitor, was approved by the FDA for patients with metastatic non–small-cell lung cancer (NSCLC) associated with the EGFR or ALK genetic mutations whose disease progressed during or after treatment with platinum-containing chemotherapy.
Related Items
2019 Fourth Annual Oncology Guide to New FDA Approvals published on June 5, 2019 in FDA Updates, Leukemia
2019 Fourth Annual Oncology Guide to New FDA Approvals published on June 5, 2019 in FDA Updates, Gastrointestinal Cancers, Drug Profiles/Updates